Higher Efficacy of Sequential Therapy with Interferon-α and Lamivudine Combination Compared to Lamivudine Monotherapy in HBeAg Positive Chronic Hepatitis B Patients

University of Delhi, Old Delhi, NCT, India
The American Journal of Gastroenterology (Impact Factor: 10.76). 12/2005; 100(11):2463-71. DOI: 10.1111/j.1572-0241.2005.00247.x
Source: PubMed


Monotherapy with interferon (IFN) or lamivudine is effective in a limited proportion of chronic hepatitis B (CHB) patients. A sequential combination may have better therapeutic effects by sustained viral suppression combined with immunomodulation.
To compare the efficacy of sequential lamivudine and IFN therapy versus lamivudine monotherapy in HBeAg positive CHB patients.
Seventy-five treatment naïve HBeAg positive patients with histologically proven CHB and alanine aminotransferase (ALT) >1.5 x ULN received lamivudine 100 mg per day for 52 wks with IFN 5 MIU per day added for 16 wks after the first 8 wks (group A, n = 38; age 30 +/- 12 yr; M:F = 35:3) or lamivudine 100 mg per day for 52 wks (group B, n = 37; age 30 +/- 16 yr; M:F = 31:6). Biochemical and virologic responses were assessed at weeks 52 and 76 and analysis was done on intention-to-treat. Serial samples were studied for the emergence of lamivudine-resistant YM552I/VDD mutations by direct sequencing.
At week 52, HBeAg loss occurred in 15 (39.5%) in group A and 14 (37.8%) in group B (p= 1.00). HBeAg loss, anti-HBe appearance, and undetectable DNA levels were seen in 26.3% and 13.5% (p= 0.249), respectively. Nine of 10 (90%) patients in group A and 1 of 5 (20%) in group B maintained the response through week 76 (p= 0.017). At week 76, 5 additional patients in group A and 3 in group B further achieved the primary end point and the overall HBeAg loss was observed in 44.7% and 18.9% (p= 0.025) and HBeAg loss, anti-HBe appearance, and undetectable hepatitis B virus (HBV) DNA levels in 36.8% and 10.8% in group A and group B, respectively (p= 0.026). At week 76, undetectable HBV DNA was seen in 39.5% and 16.2% in groups A and B, respectively (p= 0.039). Normal ALT was seen in 47.7% and 40.5% at week 52 (p= 0.489) and ALT was normal in 39.5% and 13.5% at week 76 (p= 0.018) in groups A and B, respectively. YM552I/VDD-resistant mutants emerged in 6 of 38 (15.5%) patients in group A, and 3 of 37 (8.1%) in group B (p= ns). The rate of histological improvement was comparable in the two groups.
Our results demonstrate that sequential therapy is superior to lamivudine monotherapy in achieving sustained seroconversion, ALT normalization, and HBV DNA loss. Compared to 80% with sequential therapy, only 20% Indian patients with CHB did not relapse after stopping lamivudine monotherapy.

24 Reads
  • Source
    • "The first is that BW001 induces mixed IFNs, whereas the recombinant IFN currently used is usually a single type of IFN. For instance, recombinant IFN-a 2b is used to treat hepatitis C, hepatitis B, genital warts, Kaposi's sarcoma, hairy cell leukemia, chronic myelogenous leukemia, malignant melanoma , advanced hepatocellular carcinoma, and Erdheim– Chester disease (Samuel, 2001; Braiteh et al., 2005; Kurokohchi et al., 2005; Sarin et al., 2005; Ward & Kugelmas, 2005); and IFN-b is used for the treatment of relapsing forms of multiple sclerosis (Banwell et al., 2006; Derwenskus & Lublin, 2006). Obviously, the synergistic action of mixed IFNs is more effective than a single type of IFN. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Coxsackie B3 virus (CVB3) is the most significant pathogen causing myocarditis in humans, and antiviral therapy would be most effective in the early stages of the disease. Here we provide evidence that BW001, a C-type CpG oligodeoxynucleotide, induces anti-CVB3 activity in human peripheral blood mononuclear cells (PBMCs). In parallel, we have demonstrated that BW001 induces human PBMCs to express mRNAs of multiple types of interferon (IFN), including IFN-alpha, IFN-beta, IFN-omega and IFN-gamma, and to express mRNAs of at least 11 subtypes of IFN-alpha. The induced IFNs may contribute to the anti-CVB3 activity. The results suggest that BW001 could be developed into a medication with the potential to treat CVB3 infectious diseases by inducing natural mixed IFNs.
    FEMS Immunology & Medical Microbiology 11/2007; 51(1):26-34. DOI:10.1111/j.1574-695X.2007.00266.x · 3.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic hepatitis B is an important clinical problem often leading to severe complications. In this review, the results obtained in the last few years with the use of current drugs, such as interferon and nucleo(t)side analogues, are summarized and the problems of obtaining a sustained remission, which is only achieved in a small number of patients, are discussed. The new approaches, such as the use of combinations of drugs, to optimize long-term tolerable treatment are also considered.
    Expert Review of Clinical Immunology 11/2006; 2(6):915-29. DOI:10.1586/1744666X.2.6.915 · 2.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The natural history of chronic hepatitis B should be clearly defined before appropriate recommendations for treatment can be advocated. In patients who acquire the disease in early life, the complications of chronic hepatitis B continue to occur as a result of prolonged insidious damage to the liver, even in the low viraemic phase. Treatment that ends with hepatitis B e antigen seroconversion with hepatitis B virus DNA levels just below 10(5) copies/ml may not be sufficient. Patients with mild elevation of alanine aminotransferase levels are already at considerable risk of developing complications. Treatment strategy should aim at maximal and prolonged viral suppression to the lowest possible hepatitis B virus DNA levels. Nucleotide/nucleoside analogues will become the mainstay of treatment. Future treatment strategic plans should target maximising antiviral potency and minimising the chance of drug resistance.
    Expert Opinion on Pharmacotherapy 12/2006; 7(16):2225-31. DOI:10.1517/14656566.7.16.2225 · 3.53 Impact Factor
Show more

Similar Publications